These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 20407589)

  • 1. Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.
    Brown SA; Surman SL; Sealy R; Jones BG; Slobod KS; Branum K; Lockey TD; Howlett N; Freiden P; Flynn P; Hurwitz JL
    Viruses; 2010 Feb; 2(2):435-467. PubMed ID: 20407589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.
    Bauer A; Podola L; Mann P; Missanga M; Haule A; Sudi L; Nilsson C; Kaluwa B; Lueer C; Mwakatima M; Munseri PJ; Maboko L; Robb ML; Tovanabutra S; Kijak G; Marovich M; McCormack S; Joseph S; Lyamuya E; Wahren B; Sandström E; Biberfeld G; Hoelscher M; Bakari M; Kroidl A; Geldmacher C
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28701395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.
    Asbach B; Kibler KV; Köstler J; Perdiguero B; Yates NL; Stanfield-Oakley S; Tomaras GD; Kao SF; Foulds KE; Roederer M; Seaman MS; Montefiori DC; Parks R; Ferrari G; Forthal DN; Phogat S; Tartaglia J; Barnett SW; Self SG; Gottardo R; Cristillo AD; Weiss DE; Galmin L; Ding S; Heeney JL; Esteban M; Jacobs BL; Pantaleo G; Wagner R
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens.
    Asbach B; Kliche A; Köstler J; Perdiguero B; Esteban M; Jacobs BL; Montefiori DC; LaBranche CC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Landucci G; Forthal DN; Seaman MS; Hawkins N; Self SG; Sato A; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Francis J; Galmin L; Ding S; Heeney JL; Pantaleo G; Wagner R
    J Virol; 2016 Apr; 90(8):4133-4149. PubMed ID: 26865719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.
    Bridge SH; Sharpe SA; Dennis MJ; Dowall SD; Getty B; Anson DS; Skinner MA; Stewart JP; Blanchard TJ
    Virol J; 2011 Sep; 8():429. PubMed ID: 21899739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of heterologous prime-boost immunization strategies with DNA and recombinant vaccinia virus co-expressing GP3 and GP5 of European type porcine reproductive and respiratory syndrome virus in pigs.
    Zhang H; Ren J; Li J; Zhai C; Mao F; Yang S; Zhang Q; Liu Z; Fu X
    Microb Pathog; 2023 Oct; 183():106328. PubMed ID: 37661073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines.
    Hu Z; Jiang W; Gu L; Qiao D; Shu T; Lowrie DB; Lu SH; Fan XY
    J Mol Med (Berl); 2019 Dec; 97(12):1685-1694. PubMed ID: 31786669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens.
    Ratto-Kim S; Currier JR; Cox JH; Excler JL; Valencia-Micolta A; Thelian D; Lo V; Sayeed E; Polonis VR; Earl PL; Moss B; Robb ML; Michael NL; Kim JH; Marovich MA
    PLoS One; 2012; 7(9):e45840. PubMed ID: 23049876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LL-37 antimicrobial peptide and heterologous prime-boost vaccination regimen significantly induce HIV-1 Nef-Vpr antigen- and virion-specific immune responses in mice.
    Nikyar A; Bolhassani A; Agi E
    Biotechnol Lett; 2023 Jan; 45(1):33-45. PubMed ID: 36550339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel prime-boost vaccine strategies against HIV-1.
    Excler JL; Kim JH
    Expert Rev Vaccines; 2019 Aug; 18(8):765-779. PubMed ID: 31271322
    [No Abstract]   [Full Text] [Related]  

  • 11. A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV).
    Shen YJ; Shephard E; Douglass N; Johnston N; Adams C; Williamson C; Williamson AL
    Virol J; 2011 May; 8():265. PubMed ID: 21624130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
    Manjaly Thomas ZR; Satti I; Marshall JL; Harris SA; Lopez Ramon R; Hamidi A; Minhinnick A; Riste M; Stockdale L; Lawrie AM; Vermaak S; Wilkie M; Bettinson H; McShane H
    PLoS Med; 2019 Apr; 16(4):e1002790. PubMed ID: 31039172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus.
    van Diepen MT; Chapman R; Douglass N; Galant S; Moore PL; Margolin E; Ximba P; Morris L; Rybicki EP; Williamson AL
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30760570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
    Lorin C; Vanloubbeeck Y; Baudart S; Ska M; Bayat B; Brauers G; Clarinval G; Donner MN; Marchand M; Koutsoukos M; Mettens P; Cohen J; Voss G
    PLoS One; 2015; 10(4):e0122835. PubMed ID: 25856308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
    J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterologous prime-boost H1N1 vaccination exacerbates disease following challenge with a mismatched H1N2 influenza virus in the swine model.
    Pliasas VC; Neasham PJ; Naskou MC; Neto R; Strate PG; North JF; Pedroza S; Chastain SD; Padykula I; Tompkins SM; Kyriakis CS
    Front Immunol; 2023; 14():1253626. PubMed ID: 37928521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen.
    Jones DI; Pollara JJ; Johnson-Weaver BT; LaBranche CC; Montefiori DC; Pickup DJ; Permar SR; Abraham SN; Maddaloni M; Pascual DW; Staats HF
    J Virol; 2019 Jul; 93(14):. PubMed ID: 31068425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterologous prime-boost: an important candidate immunization strategy against Tembusu virus.
    Pan Y; Jia R; Li J; Wang M; Chen S; Liu M; Zhu D; Zhao X; Wu Y; Yang Q; Yin Z; Jing B; Huang J; Zhang S; Zhang L; Liu Y; Yu Y; Tian B; Pan L; Rehman MU; Cheng A
    Virol J; 2020 May; 17(1):67. PubMed ID: 32398028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.
    Li JX; Hou LH; Meng FY; Wu SP; Hu YM; Liang Q; Chu K; Zhang Z; Xu JJ; Tang R; Wang WJ; Liu P; Hu JL; Luo L; Jiang R; Zhu FC; Chen W
    Lancet Glob Health; 2017 Mar; 5(3):e324-e334. PubMed ID: 28017642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen.
    Knudsen ML; Ljungberg K; Tatoud R; Weber J; Esteban M; Liljeström P
    PLoS One; 2015; 10(2):e0117042. PubMed ID: 25643354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.